Caribou Biosciences Inc Ordinary Shares CRBU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRBU is a good fit for your portfolio.
News
-
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
-
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
-
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
-
Caribou Biosciences to Participate in Upcoming Investor Conferences
-
Caribou Biosciences Shares Rise 4.1% as FDA Approves Lymphoma Trial
-
Caribou Biosciences offers more stock, and shares fall
-
Trending: Caribou Biosciences Scores Pfizer Investment
Trading Information
- Previous Close Price
- $3.92
- Day Range
- $3.79–4.03
- 52-Week Range
- $3.45–8.56
- Bid/Ask
- $3.80 / $3.81
- Market Cap
- $343.20 Mil
- Volume/Avg
- 1.1 Mil / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.37
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 137
- Website
- https://www.cariboubio.com
Comparables
Valuation
|
Metric
|
CRBU
|
CELC
|
BMEA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.94 | 2.99 | 2.37 |
Price/Sales | 8.37 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRBU
|
CELC
|
BMEA
|
|---|---|---|---|
Quick Ratio | 11.75 | 12.78 | 7.74 |
Current Ratio | 11.97 | 13.43 | 7.84 |
Interest Coverage | — | −12.43 | — |
Quick Ratio
CRBU
CELC
BMEA
Profitability
|
Metric
|
CRBU
|
CELC
|
BMEA
|
|---|---|---|---|
Return on Assets (Normalized) | −23.27% | −35.57% | −56.31% |
Return on Equity (Normalized) | −28.24% | −49.08% | −65.70% |
Return on Invested Capital (Normalized) | −26.03% | −39.21% | −67.02% |
Return on Assets
CRBU
CELC
BMEA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mwvsnkdwp | Vycb | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Blprkfqf | Gtxcky | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qqhdhknn | Pqlrt | $98.1 Bil | |
MRNA
| Moderna Inc | Bvzkhswn | Pbq | $39.1 Bil | |
ARGX
| argenx SE ADR | Dqbrpcfm | Hldj | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Rscyjdnp | Qpf | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ydygykb | Vpbgx | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sdfgmfbzj | Mqcjlp | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nmxnhhzv | Rhjwbz | $12.5 Bil | |
INCY
| Incyte Corp | Thdwcqlp | Zhnwlql | $11.9 Bil |